Spin the roulette wheel

An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Most Popular 3 Questions No Job Seeker Ever Wants To Be Asked? Cross Cultural Management In The Age Of Globalization Today's Best Part-Time Jobs 10 Jobs That Pay $30 An Hour Time Management: Stop Procrastination Today Scope Highlights Reasons to Purchase Benchmark GlaxoSmithKline's performance against key rivals in the ethical pharmaceutical sectorAnalyze the factors that will underscore a forecast ethical pharmaceutical sales CAGR of -2. 1% for GlaxoSmithKline over 2006-12Assess the generic threat faced by GlaxoSmithKline over the period 2006-12 and how this compares to generic risk across the Big Pharma peer set CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 3 Therapeutic strategy 5 Launch and expiry outlook 10 Externalization, geographic and molecule type strategies 13 Externalization strategy 14 Geographic strategy 15 Molecule type strategy 16 SWOT analysis 17 Strengths 17 Weaknesses 18 Opportunities 19 Threats 21 CHAPTER 2 CORPORATE HISTORY 24 Key findings 24 Background 25 M&A history 25 Wellcome 25 Glaxo 25 Glaxo Wellcome 26 Beecham 26 Smith Kline 26 SmithKline Beecham 27 Key historical drug launches by component GSK companies 28 M&A strategy 29 R&D overview 32 Current corporate structure 34 CHAPTER 3 HISTORICAL PERFORMANCE 35 Key findings 35 Introduction 36 Revenue and growth rate analysis, 2001-06 36 Revenue and growth rate vs.peer set 37 Product analysis, 2001-06 39 Growth drivers 39 Seretide/Advair 39 Avandia 40 Flixotide 40 Lamictal 40 Growth resistors 40 Seroxat 40 Augmentin 41 Serevent 41 Operating revenue and cost analysis, 2001-06 42 Operating revenue/cost analysis 43 CHAPTER 4 FORECAST PERFORMANCE 45 Key findings 45 Introduction 46 Revenue and growth rate, 2006-12 46 Product analysis, 2006-12 48 Growth drivers 53 Tykerb 53 Cervarix 54 Growth resistors 54 Seretide/Advair 54 Avandia 55 Wellbutrin 55 Zofran 56 Imigran 56 Therapy area analysis, 2006-12 58 Oncology 61 Urology & sexual health 61 Infectious disease 62 Respiratory 62 CNS 62 Endocrine, metabolic & genetic disorders 63 Therapy area focus 63 Launches and expiries analysis, 2006-12 68 Launch portfolio 69 Core portfolio 72 Expiry portfolio 74 Launch/core/expiry configuration 77 Externalization analysis, 2006-12 81 Geographic analysis, 2006-12 86 Molecule type analysis, 2006-12 89 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 95 Key findings 95 Overview 96 Respiratory 97 Seretide/Advair 97 Overview 97 Sales forecast 98 Newsflow 98 Oncology 103 Tykerb 103 Overview 103 Sales forecast 104 Newsflow 104 Cervarix 107 Overview 107 Sales forecast 108 Newsflow 108 Zofran 112 Overview 112 Sales forecast 113 Newsflow 113 CNS 115 Lamictal 115 Overview 115 Sales forecast 116 Newsflow 116 Gepirone ER 119 Overview 119 Sales forecast 120 Newsflow 120 Trexima 122 Overview 122 Sales forecast 123 Newsflow 124 Wellbutrin 126 Overview 126 Sales forecast 127 Newsflow 127 Imigran 130 Overview 130 Sales forecast 131 Newsflow 131 Endocrine, metabolic & genetic disorders 133 Avandia 133 Overview 133 Sales forecast 134 Newsflow 135 Infectious disease 139 Rotarix 139 Overview 139 Sales forecast 140 Newsflow 140 CHAPTER 6 APPENDIX 143 IMS vs.company-reported data reconciliation 143 References 146 Datamonitor reports 146 Abbreviations 146 Exchange rates 147 List of Tables Table 1: Peer set overview 37 Table 2: Operating revenue/cost analysis ($m), 2001-06 42 Table 3: Operating cost ratio analysis (% of total revenues), 2001-06 43 Table 4: Product portfolio overview, sales ($m), 2006-12 48 Table 5: Therapy area overview, sales ($m), 2006-12 58 Table 6: Launch portfolio overview, sales ($m), 2006-12 69 Table 7: Core portfolio overview, sales ($m), 2006-12 73 Table 8: Expiry portfolio overview, sales ($m), 2006-12 75 Table 9: Externally developed portfolio ($m), 2006-12 81 Table 10: Molecule type overview, sales ($m), 2006-12 89 Table 11: Key products overview 96 Table 12: Seretide/Advair: overview 97 Table 13: Seretide/Advair: sales forecast ($m), 2006-12 98 Table 14: Seretide/Advair: news flow 98 Table 15: Tykerb: overview 103 Table 16: Tykerb: sales forecast ($m), 2006-12 104 Table 17: Tykerb: news flow 104 Table 18: Cervarix: overview 107. casino players fast money makers en gambling language system gambling news uk citizens of us gambling online